New drug shows promise against rare salivary gland cancer
NCT ID NCT02780310
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the drug lenvatinib in 33 people with advanced adenoid cystic carcinoma that has returned or spread. Lenvatinib is a daily pill that blocks cancer cell growth and cuts off blood supply to tumors. The main goal is to see if the drug can shrink tumors by at least 25%.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
Basking Ridge, New Jersey, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
-
Memorial Sloan Kettering at Mercy Medical Center
Rockville Centre, New York, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- Can a targeted drug shrink rare salivary gland tumors?
- New drug cocktail targets genetic weakness in rare cancer
- Drug duo takes on rare head and neck tumors
- Rare sinus cancer study aims to clarify treatment outcomes
- New pill-chemo combo takes on hard-to-treat cancers